ACTC Stock UPDATES Advanced Cell Tech (ACTC) 0.0710 08/20/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Advanced Cell Tech (ACTC) 0.0710 $ACTC

Global Regenerative Medicines Market (Technology, Application and Geography) - Forecast to 2020
M2 - Mon Aug 18, 8:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/47gb9g/global) has announced the addition of the "Global Regenerative Medicines Market (Technology, Application and Geography) - Size, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020" report to their offering. According to a new market research repor titled, "GlobalRegenerative MedicineMarket (Technology, Applications, Geography) - Industry Analysis, Trends, Opportunities and Forecast, 2013-2020", the global regenerative medicine market will reach $ 67.6 billion by 2020 from $16.4 billion in 2013, registering a CAGR of 23.2% during forecast period (2014 - 2020). Small molecules and biologics segment holds prominent market share in the overall regenerative medicine technology market and is anticipated to grow at a CAGR of 18.9% during the forecast period. Regenerative medicines have the ability to restore the lost functionality of tissues or organs, unlike conventional medicines, which are palliative. The immense potential of these medicines in repairing or regenerating diseased organs is the major reason for intensive focus on research and development in this field. The technologies implemented for these medicines utilize various cell types including stem cells. The advancements in nanotechnology and stem cells application would account for further progress of this novel field of medicine. The global regenerative medicine market is segmented based on technologies into small molecules and biologics, gene therapy and cell therapy. Key Topics Covered: CHAPTER 1. INTRODUCTION CHAPTER 2. EXECUTIVE SUMMARY CHAPTER 3. GLOBAL REGENERATIVE MEDICINES MARKET OVERVIEW CHAPTER 4. GLOBAL REGENERATIVE MEDICINE MARKET BY TECHNOLOGIES CHAPTER 5. GLOBAL REGENERATIVE MEDICINE MARKET BY APPLICATIONS CHAPTER 6. GLOBAL REGENERATIVE MEDICINES MARKET BY GEOGRAPHY CHAPTER 7. COMPANY PROFILES Companies Mentioned: - Advanced Cell Technology - Athersys Inc. - Cytomedix - Cytori Therapeutics - Genzyme - Kinetic Concepts - Mesoblast Ltd. - NuVasive - Shire pharmaceuticals - Stem Cells For more information visit http://www.researchandmarkets.com/research/47gb9g/global

Advanced Cell Technology to Host Conference Call to Provide a Corporate Update
Business Wire - Wed Aug 06, 3:31PM CDT
Advanced Cell Technology, Inc. ("ACT"; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today will host a conference call on Monday, August 11, 2014 at 5:00 p.m. EDT during which it will provide a corporate update.

Advanced Cell Technology Secures $30 Million Equity Facility from Lincoln Park Capital
Business Wire - Thu Jul 03, 8:05AM CDT
Advanced Cell Technology, Inc. ("ACT" (OTCBB:ACTC), a leader in the field of regenerative medicine, today announced that it has entered into a $30 million common stock purchase agreement with Lincoln Park Capital Fund, LLC ("LPC" .

Global Glaucoma Therapeutics Market Forecasts & Opportunities, 2018
M2 - Wed Jul 02, 2:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zpvs7l/global_glaucoma) has announced the addition of the "Global Glaucoma Therapeutics Market Forecasts & Opportunities, 2018" report to their offering. Glaucoma is a disease of the eye in which fluid pressure within the eye increases. If left untreated the patient may lose vision and even become blind. The exact etiology of optic nerve damage due to glaucoma is not fully known, but involves mechanical compression and/or decreased blood flow in the optic nerve. Based on whether the cause of the disease is unknown or known, glaucoma is divided into two types, open angle and closed angle glaucoma. Five main classes of medical treatment are currently used to lower intraocular pressure: prostaglandins, beta blockers, alpha adrenergic agonists, carbonic anhydrase inhibitors, and fixed dose combinations. The Global Glaucoma Therapeutics market can be divided into five segments: Prostaglandins, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors, and Fixed Dose Combinations. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Glaucoma Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Allergan Inc. - Merck & Co. Inc. - Novartis AG - Pfizer Inc. Other Prominent Vendors - Acadia Pharmaceuticals Inc. - AC Immune SA - Acorn Biomedical Inc. - Advanced Cell Technology Inc. - Aerie Pharmaceuticals Inc. - Carl Zeiss Meditec Inc. - Falcon Pharmaceuticals Ltd. - Inotek Pharmaceuticals Corp. - Lexicon Pharmaceuticals Inc. - Neurotech Pharmaceuticals Inc. - NicOx SA - Otsuka Holdings Co. Ltd. - Phytopharm plc - Santen Pharmaceuticals Co. Ltd. - Senju Pharmaceutical Co. Ltd. - SIFI SpA - Valeant Pharmaceuticals International Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Product Profiles - Market Research Methodology - Introduction - Market Landscape - Pipeline Snapshot - Rate of Incidence and Prevalence - Market Segmentation by Drug Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/zp...l_glaucoma

Advanced Cell Technology, Inc. Announces Paul K. Wotton Ph.D. Recognized as Ernst & Young (EY) 2014 Entrepreneur of the Year(TM) for New Jersey Region
Business Wire - Tue Jul 01, 8:01AM CDT
Advanced Cell Technology, Inc. ("ACT" (OTCBB:ACTC), a leader in the field of regenerative medicine, today announced that Paul K. Wotton, Ph.D. was the recipient of the 2014 Ernst and Young (EY) Entrepreneur Of The Year(TM) Regional Award for the Life Sciences category in the New Jersey region. The awards program recognizes entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance and personal commitment to their businesses and communities. Dr. Wotton was selected as the award winner by a panel of independent judges and the award was presented at a gala event at the Hyatt Regency in New Brunswick on June 26th 2014.

OTC Stocks Daily Trading Focus: Windstream Technologies, Inc. Blue Earth, Inc. Creative Edge Nutrition, Inc. Brainstorm Cell Therapeutics, Inc., Advanced Cell Technology, Inc.
PR Newswire Europe - Tue Jul 01, 7:01AM CDT
LONDON, July 1, 2014 /PRNewswire/ --

Advanced Cell Technology Appoints Paul K. Wotton, Ph.D, President and Chief Executive Officer
Business Wire - Tue Jun 24, 8:10AM CDT
Advanced Cell Technology, Inc. ("ACT" (OTCBB:ACTC), a leader in the field of regenerative medicine, today announced the appointment of Paul Wotton, Ph.D., to the position of President and Chief Executive Officer. Dr. Wotton is a highly regarded veteran of the biopharmaceutical industry and has a track record of leading companies to clinical, financial and commercial success. Dr. Wotton joins ACT from Antares Pharma Inc. (NASDAQ:ATRS), where he served as President and CEO since October, 2008.

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H1 2014
M2 - Tue Jun 10, 3:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fllzwb/juvenile_macular) has announced the addition of the "Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Juvenile Macular Degeneration (Stargardt Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Juvenile Macular Degeneration (Stargardt Disease) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Sanofi - Advanced Cell Technology, Inc. - Acucela Inc. - Alkeus Pharmaceuticals, Inc. - Visum Therapeutics For more information visit http://www.researchandmarkets.com/research/fl...le_macular

New Mesenchymal Stem Cell Population from Human Pluripotent Stem Cells Displays Potent Immunomodulatory and Therapeutic Properties
Business Wire - Mon Mar 24, 3:55PM CDT
Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, and its collaborators reported today that it has discovered a new method to generate a potent and replenishable population of mesenchymal stem cells (MSCs) from pluripotent stem cells. The research appears online ahead of print in Stem Cell and Development, one of the top stem cells journals, published by Mary Ann Liebert, Inc. This new and proprietary population of pluripotent stem cell-derived MSCs displays potent immunomodulatory and therapeutic properties and has a greater than 30,000 fold proliferative capacity, relative to ordinary bone marrow-derived MSCs, the most commonly used source for MSCs in clinical trials. The paper is available free online at http://online.liebertpub.com/doi/abs/10.1089/scd.2013.0554.

OTC Daily Alert Stock Watch - Advanced Cell Technology, Inc.(OTCQB: ACTC)
WorldStockWire - Mon Mar 24, 3:31AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

Advanced Cell Technology to Present at Regenenerative Medicine Investor Day March 26, 2014
Business Wire - Fri Mar 21, 3:00PM CDT
Advanced Cell Technology (ACTC) today announced that Edward Myles, Interim President, CFO & EVP of Corporate Development, will present at the 2nd Annual Regen Med Investor Day to be held Wednesday, March 26, 2014 in New York City.

Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016
M2 - Wed Mar 12, 6:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lq46f/regenerative) has announced the addition of the "Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016" report to their offering. There is a high demand for synthetic organ transplants in the market. Regenerative medicine helps in the development of artificial organs. The introduction of artificial organs for implantation is expected to encourage many vendors and research organizations to develop advanced stem cell products, therapies, and regenerative products. It will also help reduce the long organ waiting list. For instance, custom-made windpipe can be made using regenerative products within a week. The first ever implant of a synthetic trachea took place in June 2011. The synthetic trachea was made from minuscule plastic fibers and was covered in stem cells taken from a human bone marrow. Surgeons successfully implanted this synthetic trachea into a 36-year-old patient with late-stage tracheal cancer at Karolinska University Hospital in Stockholm. Thus, the use of synthetic organs in transplant surgeries is expected to have a positive impact on the growth of the market. According to the report, one of the main drivers of this market is the increasing prevalence of degenerative diseases. Regenerative products have helped in addressing the unmet needs of various disease areas. Another major driver of the market is the significant advances seen in R&D. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Vendor Landscape 8. Buying Criteria 9. Market Growth Drivers 10. Drivers and their Impact 11. Market Challenges 12. Impact of Drivers and Challenges 13. Market Trends 14. Key Vendor Analysis 15. Other Reports in this Series Companies Mentioned: - Advanced Cell Technology Inc. - Arteriocyte Inc. - Athersys Inc. - Baxter International Inc. - CryoLife - Cytori Therapeutics Inc. - Genzyme Corp. - Geron Corp. - InVivo Therapeutics - Inc. - Integra Life Sciences Holdings Corp. - Kensey Nash Corp. - Kinetic Concepts Inc. - Medtronic Inc. - NeoStem Inc. - Osiris Therapeutics Inc. - Osteotech Inc. - RTI Biologics Inc. - Stryker Corp. - Zimmer Holdings Inc. For more information visit http://www.researchandmarkets.com/research/4l...generative

Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020
M2 - Mon Mar 10, 7:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gsw6jj/global_stem_cell) has announced the addition of the "Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020" report to their offering. The market is expected to reach revenue of $56.4 billion by 2020, growing at CAGR of 33.4% during 2013 to 2020 The study observed that the global umbilical cord blood stem cell market is forecasted to reach market value over $11.5 billion in 2014 from $ 6.5 billion in 2012. Developments and approvals for novel cord blood stem cells therapies is expected to drive the market growth. The storage service market was valued at $7.4 billion in 2013. Increase in prevalence rate of chronic diseases such as cancer, diabetes, blood disease, immune disease, metabolic disease etc. has increased the need of cost effective and efficient way of treatment. However, cord blood stem cells have the potential to treat these chronic diseases effectively. These stem cells have special property of higher cell count in lower blood volume. Collection of these stem cells is much easier than other stem cells and could be stored in specialized preservation facilities called as Cord Blood Stem Cell Banks.Cord blood stem cells market is in its emerging phase. Significant applications of stem cells in the treatment of various disorders will be commercialized very soon as most of them are in the last phase of clinical trials. Patents for collection techniques and therapeutics methods are approved by respective government of developed countries however patents for UCB stem cells are comparatively less in developing economies. According to lead analyst Debbie Shields, the geographic analysis shows that the North American market for cord blood stem cell would account for approx. 44% of total revenue generated by the cord blood market in 2013. However, much expected growth is to occur in Asia-Pacific regions during the forecast period, because of growing demand for chronic disease treatments and widely increasing awareness levels. This report study offers updated review about major market players present in this market such as researcher based pharmaceutical companies and therapeutics services companies. Key Market Segments Global Stem cell UCB market by storage - Public cord blood banks - Private cord blood banks - Public Vs. Private UCB banks Global Stem cell UCB market by Diseases - Cancer/ Oncology diseases - Acute Leukemia - Chronic Leukemia - High Risk Solid Tumors - Myelodysplastic Syndrome - Blood diseases - Aplastic Anemia - Beta Thalassemia - Sickle Cell disease - Immune Disorders - Leukocyte Adhesion Deficiency - Hystiocytic Disorders - Wiskott-Aldrich - Metabolic Disorders - Krabbe Disease - Hurler Syndrome - Sanfilippo Syndrome - Other diseases - Osteopetrosis - Hemophagoyticlymphohistiocytosis Global Stem cell UCB market by Technology - Stem Cell Transplant - Autologous transplant - Allogenic transplant - Transplant Medicine - Regenerative Medicine - Others - Cord Blood Banking - Blood Transfusion - Cell Based Genetics Companies Mentioned - Advanced Cell Technology Inc. (USA) - Athersys Inc. - California Stem Cell - Cytori Therapeutics Inc. - Geron Corporation - Mesoblast Limited - NeoStem Inc. - Opexa Therapeutics Inc. - Osiris Therapeutics - Pluristem Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/gs..._stem_cell

Global Cell Therapy Market & Pipeline Insight Research Report
M2 - Tue Mar 04, 3:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/5kmmgq/global_cell) has announced the addition of the "Global Cell Therapy Market & Pipeline Insight" report to their offering. Research in cell therapy is transforming the future of medicine. As the life of a human being begins as a cell, these cells undergo a highly complex set of events and finally those few stems become capable of self-renewal and differentiation and develop into the specialized cells in the body. Cell therapy research also offers significant potential for restructuring the method of medical practice. Over the past 3-5 years, a more complex therapeutic modality has been is emerging as cell therapies which have been developed to treat diseases which are not amenable to treatment with more classical pharmaceutical or biopharmaceutical products. This market offers the promise of successfully regenerating damaged tissues and organs in the body by replacing the damaged tissue and/or by stimulating the body's own repair mechanisms to heal previously irreparable tissues. With their rising popularity, these therapies are becoming more cost effective and efficient. The global market for cell therapy was valued at close to USD 2.5 Billion in 2012. With continuous advances and developments in this field of medicine, the global cell therapy market is expected to grow at a high rate of 20-22% to reach approximately USD 8 Billion by 2018. Several products and technologies of cell-based therapies are in the R&D pipeline are expected to enter the market during the forecast period, thus resulting in an increased growth rate. It is most likely that the new improved technologies would revolutionize the area of bio-pharma and personalized medicine. Development of sophisticated automation devices for cell expansion and culture process for use in the treatment is one of the emerging trends of ACT market. With the cell-based therapies growing by leaps and bounds, it is expected that the future years would witness significant advancements in technology in the cell therapy market. Increasing incidence of diseases along with lack of adequate effective treatment for these diseases is most likely to drive the cell therapy technology in developed and developing nations. Among the emerging trends of the global market, the most prominent one is the development of sophisticated automation devices for cell expansion and culture process which could be used in the treatment of life threatening diseases. Global Cell Therapy Market & Pipeline Insight Report Highlights & Findings: - Introduction to Cell therapy - Global Cell Therapy Market Overview - Global Cell Therapy Market Dynamics - Cell Therapy Pipeline by Phase, Country & Target Indications - Cell Therapy Drugs in Pipeline: More Than 200 - Highest Number of Drugs in Preclinical Stage: 73 - Number of Drugs in Phase I/II Stage: 35 - Key Market: US - Majority Cell therapies For Cancer Treatment Companies Mentioned - Advanced Cell Technology - Amgen - California Stem Cell - Celgene Corporation - Cytomedix - Fibrocell Science - Genzyme - NeoStem - Novartis - Stemedica Cell Technologies For more information visit http://www.researchandmarkets.com/research/5k...lobal_cell About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Advanced Cell Technology Announces Change in Management
Business Wire - Wed Jan 22, 7:30AM CST
Advanced Cell Technology (OTC:ACTC) today announced that Gary Rabin will leave the Chief Executive Officer position, effective immediately. The board has appointed the Company's CFO and Executive Vice President of Corporate Development, Edward Myles, as interim President. The board will initiate a search for a permanent CEO.

2013 Report on the International Regenerative Medicine Markets
M2 - Mon Jan 13, 8:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/3gvqj4/regenerative) has announced the addition of the "2013 Report on the International Regenerative Medicine Markets" report to their offering. Astounding new advancements in the ability to repair or replace damaged human tissue and organ functions are being made. Whereas before, remedies for damaged tissue or organ functions due to congenital deformities, injuries, diseases or simple wear-and-tear relied upon either the body's ability to repair itself (or not), or a surgeon's skilled hands. Now, the area of regenerative medicine promises to revolutionize humanity's ability to remediate countless physical maladies that have perpetually afflicted humans and other animals. Compared to a select few life forms--like the starfish--man-made solutions for tissue repair and organ replacement haven't come close to nature's solutions. And where there once was no solution even offered by nature, researchers are now at the cusp of overcoming such limitations by "2013 Report on the International Regenerative Medicine Markets", enables the reader gain in-depth knowledge about ongoing tissue engineering and stem cell therapy research programs carried out in universities and other research centers. Moreover, this analysis profiles the leading companies developing regenerative medicine solutions. Key Topics Covered: 1. Overview 2. Regenerative Medicines: An Overview of Segments 3. Regenerative Medicine: The Next Evolution of Medical Treatment 4. Recent Advances in Regenerative Medicine and Stem Cell Research 5. Stem Cell Industry Highlights 6. Regenerative Medicines: A Brief Update from Selected Countries 7. Market Analysis for Regenerative Medicine Sector 8. Stem Cell Industry 9. Business Models and Requirements for a Successful Regenerative Medicine Industry 10. Company Profiles Companies Mentioned: - Aastrom Biosciences, Inc. - Advanced Cell Technology, Inc. (ACT) - Aldagen, Inc. - BeFutur Biotechnologies - Cardio BioSciences - CardioPolymers, Inc. - Develogen AG - Effector Cell Institute, Inc (ECI) - Epistem plc - FivePrime Therapeutics, Inc. - Forticell Bioscience, Inc. - Geron Corporation - Hydra Biosciences, Inc. - Intercytex Group plc - Japan Tissue Engineering, Co., Ltd. - Karocell Tissue Engineering AB - LifeCell - MaxCyte, Inc. - Mesoblast Ltd. - NanoCor's Products - Olympus Terumo Biomaterials Corporation - Pervasis Therapeutics, Inc. - RegeneRx - SyntheMed, Inc. - Thermogenesis Corp. - t cure GmbH For more information visit http://www.researchandmarkets.com/research/3g...generative

Clearlake Capital Invests in PrimeSport
Marketwire - Wed Jan 08, 3:47PM CST
PrimeSport, Inc. ("PrimeSport" or the "Company" and Clearlake Capital Group, L.P. (together with its affiliates, "Clearlake" today announced that Clearlake has acquired a majority stake in PrimeSport, a leading sports travel and entertainment management company.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cambrian Turns Dairy Wastewater Into Long-Term Gas

Updated Category News Views 87

A Wisconsin dairy plant just traded lagoon duty for a 20-year service arrangement, and that is more consequential than the usual shiny renewable-gas headline. Cambrian Innovation says it has commissioned and is operating a wastewater treatment and resource recovery system that handles roughly 280,000 gallons a day. That works out to about 102 million gallons annually, a...

Continue Reading
CloudBackend's €6.6M Test: Can Vibe Code Become SaaS?

Updated Category News Views 272

A prototype is cheap theatre; keeping it alive after customers arrive is where the bill lands. CloudBackend has raised €6.6 million to attack that unglamorous, absolutely vital stretch between an AI-made app and an actual software business. The round is led by Carl-Henric Svanberg's family office, while existing backer M2 Asset Management increased its stake. That is a...

Continue Reading
Replit Bets on Trusted Creators to Sell AI Agents at Work

Updated Category News Views 127

Forty-five creators may sound like a marketing footnote, but Replit is aiming at a real enterprise bottleneck: people do not buy grand AI slogans; they buy proof that a messy internal problem can actually get fixed. Its newly launched Replit & Co. program puts business and technology creators in front of that problem, with product access, demonstrations and direct contact...

Continue Reading
A Quanzhou Table Offers China Beyond the Headlines

Updated Category News Views 35

Steam rising from a Quanzhou table can carry more weight than another polished speech about cultural exchange. That is the sensible instinct behind Home Banquets with Master Chefs, the CCTV-4 series using regional meals to explore geography, customs and memory. It is not trying to explain China through a pile of statistics or a museum-label summary. It starts where people...

Continue Reading
Youdao Sets December AGM With No Vote on the Table

Updated Category News Views 87

A shareholder meeting without a vote is more temperature check than showdown, and that is exactly what Youdao has scheduled for December 17, 2026. The company will gather shareholders from 3:00 p.m. to 5:00 p.m. Beijing time at its Beijing office, but it has made one point painfully clear: no proposal will be submitted for shareholder approval. For holders of NYSE: DAO,...

Continue Reading
Live Nation Tests Creator Content With Morgan Jay Series

Updated Category News Views 21

A comedian turning crowd work into songs is hardly a boardroom event, but this one has a useful wrinkle: Live Nation Studios put financing behind it. Morgan Jay and Austin-based agency Hello Party launched Music Therapy with Morgan Jay on YouTube on November 18, with Kam Patterson opening the season. The show pairs Jay and celebrity guests for loose conversation,...

Continue Reading
GE Aerospace Backs Service Members With $100K Gift

Updated Category News Views 82

A six-figure commitment can look tiny beside jet-engine budgets, yet it can matter a great deal when it reaches people navigating the awkward jump from military service into civilian life. GE Aerospace has committed $100,000 to Embry-Riddle Aeronautical University to support transitioning service members. That is the whole heart of this announcement, and frankly, it is...

Continue Reading
CHN Energy's Indonesia Record Deserves a Hard Look

Updated Category News Views 56

Twenty years of boots sinking into swamp mud tells a sturdier story than a polished anniversary slogan. CHN Energy says it entered Indonesia's energy market two decades ago and has since built an operating presence around reliable electricity, local training and community work. In a country scattered across thousands of islands, dependable power is not some decorative...

Continue Reading
Institutions Spread AI Bets as 2027 Risks Mount Higher

Updated Category News Views 35

Money managers are not fleeing the party; they are checking the fire exits. Natixis Investment Managers surveyed 515 institutions overseeing $42.7 trillion, and their 2027 posture is pretty plain: keep taking risk, just stop pretending every risk is the same. Inflation, rates, government debt, geopolitical fracture and an AI spending boom are all tugging at portfolios at...

Continue Reading
Nellie's 50% Booking Jump Reveals a Quieter Luxury

Updated Category News Views 161

Silicon Valley’s rich are apparently tired of performing wealth for strangers, and frankly, that tracks. Nellie’s 2027 forecast says its mostly tech-money clientele is moving past the old trophy case of private jets, famous resort towns, and suites priced like small houses. The prize now is privacy, a clean schedule, and somebody competent fixing the ugly little...

Continue Reading
on>

Top 5 Most Recently Viewed Articles

Virtusa Partners with Wiley to Drive Technological Change

Updated Category News Views 234

Virtusa Partners with Wiley to Drive Technological Change Virtusa Corporation, recognized globally for its leadership in digital business strategy and AI-driven platform engineering, has entered into an exciting partnership with Wiley, a key player in authoritative content and research intelligence. This collaboration aims to foster Wiley's technology transformation over...

Continue Reading
AZZ Inc. Declares Q2 2025 Dividend of $0.17 per Share

Updated Category News Views 67

AZZ Inc. Declares Dividend for the Second Quarter of 2025 AZZ Inc. (NYSE: AZZ), recognized for its leadership in hot-dip galvanizing and coil coating services, has recently notified its shareholders about a significant financial decision. The Board of Directors has approved a second quarter cash dividend amounting to $0.17 per share. This dividend will be allocated to all...

Continue Reading
Tampa General Hospital's Ambulatory Centers Achieve Top Rankings

Updated Category News Views 233

Tampa General Hospital's Ambulatory Centers Recognized The TGH Outpatient Center and TGH Surgery Center at Morsani have earned a prestigious spot among the top five ambulatory surgery centers in the state. Tampa General Hospital (TGH) proudly announces this recognition from a leading publication for the fourth consecutive year. Achievements in Ambulatory Surgery According...

Continue Reading
Norsk Hydro's Resilience Amid Market Challenges: A Detailed Overview

Updated Category News Views 218

Norsk Hydro's Recent Financial Performance Norsk Hydro reported significant financial results for the third quarter, with an adjusted EBITDA of NOK 5,996 million. This showcases a reduction from the NOK 7,367 million recorded in the same period last year, largely attributed to decreased alumina prices and robust NOK dynamics. However, these challenges were mitigated by...

Continue Reading
Top Aerospace and Defense Contractors Shaping the Future

Updated Category News Views 2184

Aerospace and Defense: A Key Industry The aerospace and defense sector is crucial for national security as well as a significant player in the stock market. With the U.S. leading the globe in defense spending, the largest contractors are poised for expansion amid global tensions. Here’s a breakdown of the top 10 largest U.S. defense contractors based on revenue,...

Continue Reading